Clinical Trials in Czechia — Country Dashboard | 1,510 EU Studies

Filter these 1,510 trials by condition, phase, sponsor and more.

Open in Search →

1,510 Registered trials

549 Recruiting

863 Completed trials

466 Sponsors active

568 Research sites

Phase III

Phase II

Phase III: 879 Phase II/III: 76 Phase II: 349 Phase I/II: 33 Phase III/IV: 13 Phase IV: 38 Phase I: 16 Phase I (Other): 40 Phase I (FiH): 14 Other: 52

Oversight events in trials active here:

67 serious breaches 465 temporary halts 21 urgent safety measures 48 unexpected events 73 corrective measures across 203 trials

View oversight register →

Top conditions

Non-small cell lung cancer 21 Crohn's disease 18 Prostate cancer metastatic 15 Colitis ulcerative 15 Pulmonary arterial hypertension 15 Asthma 14 Ovarian cancer 13 Systemic lupus erythematosus 12 Obesity 12 Multiple sclerosis 12 Dermatitis atopic 12 Diffuse large B-cell lymphoma 11

Top sponsors

Novartis Pharma AG 86 Merck Sharp & Dohme LLC 66 Janssen - Cilag International 58 Sanofi-Aventis Recherche & Developpement 53 AstraZeneca AB 50 AbbVie Deutschland GmbH & Co. KG 45 Pfizer Inc. 42 F. Hoffmann-La Roche AG 35 Bristol-Myers Squibb Services Unlimited Company 29 Amgen Inc. 27 Boehringer Ingelheim International GmbH 27 Eli Lilly & Co. 25

Cities with most trials

All 183 cities →

All trials — page 4

1,510 total

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myo… Pending

2025-524100-29-00 Phase I (Other) Seropositive autoimmune disease: Sjogren’s disease or idiopa… Ouro Medicines Limited
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Phase III Treatment-naїve mantle cell lymphoma (MCL) Innocare Pharma Inc.
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Phase III Non-active Secondary Progressive Multiple Sclerosis (SPMS) Zenas Biopharma (USA) LLC
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, sing… Pending

2025-524376-36-00 short-term treatment of insomnia Orion Corporation
Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-II… Pending

2025-524553-13-00 Phase II lung and/or heart failure Fakultni Nemocnice Ostrava
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Phase II Ulcerative colitis (Inflammatory Bowel Disease) Spyre Therapeutics Inc.
Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinica… Pending

2025-524673-16-00 Phase II Autism spectrum disorder Masarykova Univerzita
Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers Pending

2025-524720-22-00 Phase II patients with head and neck squamous cell carcinoma (HNSCC) Fakultni Nemocnice Kralovske Vinohrady
A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease. Pending

2025-524855-30-00 Phase III Cutaneous Manifestations of Lupus Erythematosus With or With… Merck Healthcare KGaA
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects. Pending

2025-524871-22-00 Healthy subjects Pevisal Group Farmaceutici S.r.l.
A Phase II study to investigate lung function with 2 different doses of inhaled glycopyrronium taken with BFF compared to BFF in participant… Pending

2025-524914-26-00 Phase II Asthma AstraZeneca AB
A study comparing different dosage forms of midazolam and how they are taken up in the body. Pending

2025-524999-37-00 Phase I (Other) Bioavailability Study under Fasting Conditions MIDAS Pharma GmbH
Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers Pending

2026-525448-14-00 Parkinson disease Orion Corporation
A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Interme… Pending

2026-525531-16-00 Phase III Non-Muscle Invasive Papillary Bladder Cancer Hamlet BioPharma AB
Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO) Pending

2026-525770-19-00 Phase IV Labour induction Fakultni Nemocnice Brno
Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates Pending

2026-526044-12-00 Phase IV Obesity Institute For Clinical And Experimental Medicine
Bioequivalence Study of Dapagliflozin 10 mg Pending

2026-526840-10-00 Not applicable (submitted trial is a BE study in healthy par… Vipharm S.A.
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting

2025-524404-29-00 Phase II Ulcerative Colitis, Active Moderate Eli Lilly & Co.
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 Phase III small cell lung cancer Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting

2025-521038-27-00 Phase III Immune system diseases Sanofi-Aventis Recherche & Developpement
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem… Recruiting

2025-521390-14-00 Phase II Acute Myeloid Leukemia Pediatric Research International GmbH
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) Recruiting

2025-524894-17-00 Phase II/III Neovascular age-related macular degeneration (NVAMD) Eyebiotech Limited
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Recruiting

2024-516896-34-00 Phase I/II progressive/relapsed/refractory pediatric low-grade glioma (… Universitaetsklinikum Heidelberg AöR
An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Recruiting

2025-523443-35-00 Phase III Persistent Corneal Epithelial Defect (PCED) Dompe' Farmaceutici S.p.A.

Showing 73–96 of 1,510 trials

← All countries